ストックスクリーナーアプリを入手
1.40
3.70%
0.05
プレマーケット:
1.40
前日終値:
$1.35
開ける：
$1.36
24時間の取引高:
4.31M
Relative Volume:
1.38
時価総額：
$1.11B
収益：
$711.41M
当期純損益:
$-133.73M
株価収益率:
-7.3684
EPS:
-0.19
ネットキャッシュフロー:
$-199.99M
1週間 パフォーマンス:
+4.48%
1か月 パフォーマンス:
+8.53%
6か月 パフォーマンス:
-6.67%
1年 パフォーマンス:
-6.04%
1日の値動き範囲:
$1.35
$1.43
1週間の範囲:
$1.32
$1.43
52週間の値動き範囲:
$1.21
$2.035
Opko Health Inc Stock (OPK) Company Profile
OPK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.40 | 1.06B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
404.94 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
188.07 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.87 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.04 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.96 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-25 | 開始されました | JP Morgan | Neutral |
| 2023-06-29 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-24 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 開始されました | Ladenburg Thalmann | Buy |
| 2019-11-25 | 開始されました | Piper Jaffray | Overweight |
| 2018-03-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-09-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 繰り返されました | Standpoint Research | Buy |
| 2016-06-03 | 開始されました | Standpoint Research | Buy |
| 2016-03-31 | 繰り返されました | Barrington Research | Outperform |
| 2015-10-16 | 開始されました | JP Morgan | Overweight |
| 2015-09-11 | ダウングレード | Jefferies | Buy → Hold |
| 2015-03-03 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 繰り返されました | Oppenheimer | Outperform |
| 2014-03-14 | 開始されました | Oppenheimer | Outperform |
| 2013-11-13 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2013-05-30 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-10-22 | 開始されました | Barrington Research | Outperform |
| 2011-12-01 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2011-07-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Opko Health Inc (OPK) 最新ニュース
What drives OPKO Health Inc. stock priceConsistently high yield - jammulinksnews.com
OPKO Health Inc. Stock Analysis and ForecastDynamic investment opportunities - jammulinksnews.com
What analysts say about OPKO Health Inc. stockSkyrocketing returns - Autocar Professional
Is OPKO Health Inc. a good long term investmentOutstanding yields - Autocar Professional
OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by LADENBURG THALM/SH SH - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Receives $2.75 Consensus Price Target from Analysts - MarketBeat
H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 - MSN
Opko Health (OPK) Has a New Rating from Ladenburg Thalmann & Co. - The Globe and Mail
Capital Advisors Inc. OK Increases Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health and Entera Bio Announce Abstract on PK/PD of - GlobeNewswire
OPKO Health and Entera Bio abstract selected for ESPEN Congress - StreetInsider
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress - Yahoo Finance
Breakthrough: First-Ever Oral Tablet Could Replace Daily Injections for Short Bowel Syndrome Treatment - Stock Titan
Investor Network: OPKO Health, Inc. to Host Earnings Call - ACCESS Newswire
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025 - MSN
OPKO Health's Russell 2000 Defensive Index Inclusion: A Catalyst for Strategic Revaluation - AInvest
10 Best Healthcare Penny Stocks to Buy According to Analysts - Insider Monkey
OPKO and Entera to present data on oral obesity treatment at ENDO 2025 - Investing.com Nigeria
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting - OPKO Health, Inc.
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT - Yahoo Finance
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
Shareholders in OPKO Health (NASDAQ:OPK) have lost 51%, as stock drops 6.5% this past week - simplywall.st
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
Quote - OPKO Health, Inc.
Bone Cancer Drugs Market Set to Witness Significant Growth - openPR.com
Bank of America Corp DE Has $855,000 Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy (NASDAQ:OPK) - Seeking Alpha
ModeX assembles advisory board for antibody development By Investing.com - Investing.com India
ModeX assembles advisory board for antibody development - Investing.com
OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - The Manila Times
OPKO Health's (OPK) ModeX Therapeutics Forms Scientific Advisory Board - StreetInsider
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire Inc.
Nuveen Asset Management LLC Boosts Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
BNP Paribas Financial Markets Cuts Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Two Sigma Investments LP - MarketBeat
Peptide Therapeutics Market Growth Set to Surge Significantly - openPR.com
Opko Health Inc (OPK) 財務データ
収益
当期純利益
現金流量
EPS
Opko Health Inc (OPK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 11 '24 |
Buy |
1.56 |
500,000 |
781,050 |
212,411,477 |
2.04%
1.25%
大文字化:
|
ボリューム (24 時間):